A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases

Journal of Investigative Dermatology

Volumn 112, Issue 5, 1999, Pages 729-738

  Mollison, Karl W ^a   Fey, Thomas A ^a   Gauvin, Donna M ^a   Kolano, Robin M ^a   Sheets, Michael P ^a   Smith, Morey L ^a   Pong, Melissa ^a   Nikolaidis, Nikolaos M ^a   Lane, Benjamin C ^a   Trevillyan, James M ^a   Cannon, John ^a   Marsh, Kennan ^a   Carter, George W ^a   Or, Yat Sun ^a   Chen, Yung Wu ^a   Hsieh, Gin C ^a   Luly, Jay R ^a,b  

^a ABBOTT LABORATORIES   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Atopic dermatitis; Contact dermatitis; Corticosteroids; Psoriasis

Indexed keywords

ABT 281; ASCOMYCIN; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; DONOVEX; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; HYDROCORTISONE; LACTAM DERIVATIVE; TRIAMCINOLONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CONTACT DERMATITIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG POTENCY; FEMALE; HELPER CELL; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RAT; SKIN ABSORPTION; SWINE; T LYMPHOCYTE ACTIVATION;

EID: 0032941677     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1999.00567.x     Document Type: Article

References (70)

1. Asadullah K, Sterry W, Stephanek K, et al: IL-10 is a key cytokine in psoriasis. J Clin Invest 101:783-794, 1998
2. Bartek MJ, LaBudde JA, Maibach HI: Skin permeability in vivo: comparison in rat, rabbit, pig and man. J Invest Dermatol 58:114-123, 1972
3. Bonifati C, Trento E, Cordiali-Fei P, et al: Increased interleukin-7 concentrations in lesional skin and in the sera of patients with plaque-type psoriasis. Clin Immunol Immunopathol 83:41-44, 1997
4. Brand CU, Hunziker T, Schaffner T, Limat A, Gerber HA, Braathen LR: Activated immunocompetent cells in human skin lymph derived from irritant contact dermatitis: an immunomorphological study. Br J Dermatol 132:39-45, 1995
5. Brasch J, Burgard J, Sterry W: Common pathogenetic pathways in allergic and irritant contact dermatitis. J Invest Dermatol 98:166-170, 1992
6. Charlesworth EN: Practical approaches to the treatment of atopic dermatitis. Allergy Proc 15:269-274, 1994
7. Cooper KD: Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol 102:128-137, 1994
8. Corsini AC, Bellucci SB, Costa MG: A simple method of evaluating delayed type hypersensitivity in mice. J Immunol Methods 30:195-200, 1979
9. Costello R, Imbert J, Olive D: Interleukin-7, a major T-lymphocyte cytokine. Eur Cytokine Network 4:253-262, 1993
10. Fukuoka M, Ogino Y, Sato H, Ohta T, Komoriya K, Nishioka J, Katayama I: RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol). Br J Dermatol 138:63-70, 1998
11. Funk JO, Maibach HI: Horizons in pharmacologic intervention in allergic contact dermatitis. J Am Acad Dermatol 31:999-1014, 1994
12. Garrigue JL, Nicolas JF, Demidem A, Bour H, Viac J, Thivolet J, Schmitt D: Contact sensitivity in mice: differential effect of vitamin D3 derivative (calcipotriol) and corticosteroids. Clin Immunol Immunopathol 67:137-142, 1993
13. Goebeler M, Toksoy A, Spandau U, Engelhardt E, Brocker E, Gillitzer R: The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic lesions. J Pathol 184:89-95, 1998
14. Gottlieb AB: Immunologic mechanisms in psoriasis. Acad Dermatol 18:1376-1380, 1988
15. Gottlieb AB, Grossman RM, Khandke I., et al: Studies of the effect of cyclosporine in psoriasis in vivo: Combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol 98:302-309, 1992
16. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1:442-447, 1995
17. Grewe M, Gyufko K, Schopf E, Krutmann J: Lesional expression of interferon-gamma in atopic eczema. Lancet 343:25-26, 1994
18. Grewe M, Bruijnzeel-Koomen CA, Schopf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T, Krutmann J: A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 19:359-361, 1998
19. Griffiths CEM, Voorhces JJ: Psoriasis, T cells and autoimmunity. J R Soc Med 89:315-319, 1996
20. Hanifin JM: Assembling the puzzle pieces in atopic inflammation. Arch Dermatol 132:1230-1232, 1996
21. Hanifin JM, Chan SC: Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Am Acad Dermatol 105:84S-88S, 1995
22. Hanifin J, Chan SC: Diagnosis and treatment of atopic dermatitis. Dermatol Ther 1:9-18, 1996
23. Hanifin JM, Schneider LC, Leung DYM, et al: Recombinant interferon-gamma therapy for atopic dermatitis. J Am Acad Dermatol 28:189-197, 1993
24. Hatanaka H, Kino T, Miyata S et al: FR-900520 and FR-900523, novel immunosuppressants isolated from A streptomyces. II. Fermentation, isolation and physico-chemical and biological characteristics. J Antibiotics XLI:1592-1601, 1988
25. Hoefakker S, Caubo M, van't Erve EHM, et al: In vivo cytokine profiles in allergic and irritant contact dermatitis. Contact Derm 33:256-266, 1995
26. Homey B, Assmann T, Vohr HW, et al: Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. J Immunol 160:5331-5340, 1998
27. Hsieh GC, Kolano RM, Andrews JW, et al: Immunosuppressant effects on improved guinea pig contact hypersensitivity (CH) model: induction with DNFB and elicitation with DNCB. FASEB J 10:A1221, 1996
28. Hsieh GH, Kolano RM, Gauvin DM, et al: Development of a swine contact hypersensitivity (CH) model - sensitization with DNFB and elicitation with DNCB for evaluating topical inhibitors. J Invest Dermatol 108:671, 1997
29. Jeffes WM, III, McCullough JL, Pittelkow MR, et al: Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 104:183-188, 1995
30. Kondo S, Sauder DN: Epidermal cytokines in allergic contact dermatitis. J Am Acad Dermatol 33:786-800, 1995
31. Krueger JG, Wolfe JT, Nabeya RT, et al: Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 182:2057-2068, 1995
32. Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L: Efficacy and safety of oral cyclosporin A (CyA; Sandimmun®) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 130:366-375, 1994
33. Lauerma AI, Surber C, Maibach HI: Absorption of topical tacrolimus (FK506) in vitro through human skin: comparison with cyclosporin A. Skin Pharmacol 10:230-234, 1997
34. Lea AP, Goa KL: Calcipotriol: a review of its pharmacological properties and therapeutic efficacy in the management of psoriasis. Clin Immunother 5:230-248, 1996
35. Lebwohl M, Abel E, Zanolli M, Koo J, Drake L: Topical therapy for psoriasis. Int J Dermatol 34:673-684, 1995
36. Lee RE, Gaspari AA, Lotze MT, Chang AE, Rosenberg SA: Interleukin 2 and psoriasis. Arch Dermatol 124:1811-1815, 1998
37. Lemster BH, Carroll PB, Rilo HR, Johnson N, Nikaein A, Thomson AW: IL-8/ 1L-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin Exp Immunol 99:148-154, 1995
38. Leung DYM: Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol 107:25-30, 1997
39. Liem WH, McCullough JE, Weinstein GD: Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis 55:306-310, 1995
40. Mahrle G, Schulze HJ, Färber L, Weidinger G, Steigleder GK: Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 32:78-88, 1995
41. Meingassner JG, Stütz A: Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 98:851-855, 1992
42. Menssen A, Trommler P, Vollmer S, et al: Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol 155:4078-4083, 1995
43. Michel G, Auer H, Kemeny L, Bocking A, Ruzicka T: Antioncogene P53 and mitogenic cytokine Interleukin-8 aberrantly expressed in psoriatic skin are inversely regulated by the antipsoriatic drug tacrolimus (FK506). Biochem Pharmacol 51:1315-1320, 1996
44. Mollison KW, Fey TA, Krause RA, Thomas VA, Mehta AP, Luly JR: Comparison of FK-506, rapamycin, ascomycin and cyclosporine in mouse models of host-versus-graft disease and heterotopic heart transplantation. Ann NY Acad Sci 685:55-57, 1993
45. Mollison KW, Fey TA, Gauvin DM, et al: Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. Curr Pharmacol Design 4:367-381, 1998
46. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. L Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348-2357, 1986
47. Nair X, Nettleton D, Clever D, Tramposch KM, Ghosh S, Franson RC: Swine as a model of skin inflammation. Inflammation 17:205-215, 1993
48. Ohmen JD, Hanifin JM, Nickoloff BJ, et al: Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J Immunol 154:1956-1963, 1995
49. Or YS, Clark RF, Xie Q, McAlpine J, Whittern DN, Henry R, Luly JR: The chemistry of ascomycin: structure determination and synthesis of pyrazole analogues. Tetrahedron 49:8771-8786, 1993
50. Phillips TJ, Dover JS: Recent advances in dermatology. N Engl J Med 326:167-178, 1992
51. Powles AV, Cook T, Hulme B, et al: Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporin for psoriasis. Br J Dermatol 128:159-165, 1993
52. Reifenrath WG, Chellquist EM, Shipwash EA, Jederberg WW, Krueger GG: Percutaneous penetration in the hairless dog, weanling pig and grafted athymic nude mouse: evaluation of models for predicting skin penetration in man. Br J Dermatol 111:123-135, 1984
53. Ruzicka T, Bicber T, Schopf E et al: A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 337:816-821, 1997
54. Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A: The annual cost of psoriasis. J Am Acad Dermatol 28:422-425, 1993
55. Schlaak JF, Buslau M, Jochum W, et al: T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 102:145-149, 1994
56. Spuls PI, Witkamp L, Bossuyt PMM, Bos JD: A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 137:943-949, 1997
57. Stoughton RB, Cornell RC. Corticosteroids. In: Fitzpatrick TB, Eisen AZ, Wolf K, Freedberg IM, Austen KF (eds). Dermatology in General Medicine, II. New York; McGraw-Hill, Inc., 1993: pp 2846-2850
58. Strange P, Cooper KD, Hansen ER et al: T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation. J Invest Dermatol 101:695-700, 1993
59. Sumimoto S, Kawai M, Kasajima Y, Hamamoto T: Increased plasma tumour necrosis factor-alpha concentration in atopic dermatitis. Arch Dis Child 67:277-279, 1992
60. Twist VW, Barnes RD: Popliteal lymph node weight gain assay for graft-versus-host reactivity in mice. Transplantation 15:182-185, 1973
61. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ: The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 101:701-705, 1993
62. Vallat VP, Gilleaudeau P, Battat L, et al: PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 180:283-296, 1994
63. Van der Ploeg I, Tehrani MJ, Matuseviciene G, Wahlgren CF, Fransson J, Scheynius A: IL-13 over-expression in skin is not confined to IgE-mediated skin inflammation. Clin Exp Immunol 109:526-532, 1997
64. Van Joost T, Kozel MMA, Tank B: Cyclosporine in atopic dermatitis: modulation in the expression of immunologic markers in lesional skin. J Am Acad Dermatol 27:922-928, 1992
65. Vollmer S, Menssen A, Trommler P, Schendel D, Prinz JC: T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol 24:2377-2382, 1994
66. Werfel T, Hentschel M, Renz H, Kapp A: Analysis of the phenotype and cytokine pattern of blood and skin derived nickel specific T cells in allergic contact dermatitis. Int Arch Allergy Immunol 113:384-386, 1997
67. Wierenga EA, Snoek M, de Groot C, et al: Evidence for compartmentalization of functional subsets of CD2* lymphocytes in atopic patients. J Immunol 144:4651-4656, 1990
68. Wrone-Smith T, Nickoloff BJ: Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878-1887, 1996
69. Ying S, Taborda-Barata L, Meng Q, Humbert M, Kay AB: The kinetics of allergen-induced transcription of messenger RNA for monocyte chemotactic protein-3 and RANTES in the skin of human atopic subjects: relationship to cosinophil, T cell, and macrophage recruitment. J Exp Med 181:2153-2159, 1995
70. Zonneveld IM, Rubins A, Jablonska S, et al: Topical tacrolimus is not effective in chronic plaque psoriasis. Arch Dermatol 134:1101-1102, 1998